Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed later-stage tilt small index

Reducing Time to Vaginal Delivery: later-stage trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Reducing Time to Vaginal Delivery: 1 US clinical trial tracked, none currently recruiting.

Reducing Time to Vaginal Delivery is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Ferring Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition reducing-time-to-vaginal-delivery

OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Reducing Time to Vaginal (th…0%
Open-enrollment share among volume-matched conditions near Reducing Time to Vaginal Delivery

Reducing Time to Vaginal Delivery has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Reducing Time to Vaginal Delivery on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Reducing Time to Vaginal Delivery is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Reducing Time to Vaginal Delivery records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Dinoprostone Vaginal Insert (DVI) Drug
1 trials
MVI 200 Drug
1 trials

US sites by state

Facility locations filed on Reducing Time to Vaginal Delivery trials. A trial with sites in several states counts in each.

New Mexico 1 trials
New Jersey 1 trials
North Carolina 1 trials
Missouri 1 trials
Michigan 1 trials
Kansas 1 trials
Indiana 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Reducing Time to Vaginal Delivery page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Reducing Time to Vaginal Delivery trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Ferring Pharmaceuticals sponsors the most Reducing Time to Vaginal Delivery trials on record, review their full trial history before evaluating a specific study. See Ferring Pharmaceuticals's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Reducing Time to Vaginal Delivery condition card totals 1 registered trials; most-linked intervention Dinoprostone Vaginal Insert (DVI); top US site state New Mexico. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.